Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP: PHRRF )

0.1521 -0.0009 (-0.59%)
Streaming Delayed Price Updated: 12:15 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pharmather Hldgs Ltd

< Previous 1 2 Next >
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
The FDA Assigned Goal Date is October 29, 2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update for Expected FDA Approval of Ketamine
Assigned FDA approval goal date of April 29, 2024, is still on track 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Provides Corporate Update
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
From PharmaTher Holdings Ltd.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.